根治性前列腺切除术后生化失败患者PSMA PET/CT引导放疗的长期结局:5年随访分析
单中心回顾性研究纳入100例根治性前列腺切除术后生化复发或PSA持续患者,接受[⁶⁸Ga]Ga-PSMA-11 PET/CT引导的挽救性放疗。中位随访59个月,36%治疗失败,生化复发与PSA持续组无差异;放疗前PSA≥0.5 ng/ml组治疗失败HR为2.2(p<0.039)。
要点
- 放疗前PSA≥0.5 ng/ml较<0.5 ng/ml治疗失败HR 2.2(p<0.039)。
- 中位随访59个月,36%治疗失败,生化复发与PSA持续组无差异。
- 治疗失败者中64%复发时PSMA PET/CT阳性,39%接受新的PSMA PET/CT引导放疗。
主要发现
- 63例为生化复发,37例为PSA持续;15例放疗前PSA<0.5 ng/ml,75例放疗前PSA≥0.5 ng/ml。
- [⁶⁸Ga]Ga-PSMA-11 PET/CT阳性52例,生化复发患者更常见局部复发,PSA持续患者更常见淋巴结受累。
- PSA持续患者中57%接受挽救性放疗联合雄激素剥夺治疗。
- 放疗前PSA≥0.5 ng/ml组较<0.5 ng/ml组治疗失败HR 2.2(p<0.039)。
- 中位随访59个月,36%治疗失败,生化复发与PSA持续组间无差异;治疗失败者中64%复发时[⁶⁸Ga]Ga-PSMA-11 PET/CT阳性,39%接受新的PSMA PET/CT引导放疗,末次分析时全部存活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the role of PSMA PET/CT-guided salvage radiotherapy (sRT) in improving long-term biochemical recurrence-free survival (bRFS) in patients with biochemical recurrence (BCR) or PSA persistence (PERS) after radical prostatectomy (RP) for localized prostate cancer. METHODS: This single-center retrospective study included 100 patients with BCR or PERS after RP who underwent [⁶⁸Ga]Ga-PSMA-11 PET/CT and sRT according to EAU guidelines. The primary endpoint was bRFS (PSA ≤ 0.2 ng/ml). RESULTS: Sixty-three patients had BCR and 37 had PERS. Fifteen patients had PSA pre-RT < 0.5 ng/ml, while 75 had PSA pre-RT ≥ 0.5 ng/ml. [⁶⁸Ga]Ga-PSMA-11 PET/CT was positive in 52 patients, with BCR patients more frequently exhibiting local recurrence while PERS patients showed more nodal involvement. Patients with PERS received sRT and androgen deprivation therapy (ADT) in 57% of cases. The hazard ratio (HR) of treatment failure for patients with PSA pre-RT ≥ 0.5 ng/ml vs. < 0.5 ng/ml was 2.2 (p < 0.039). With a median follow-up of 59 months, treatment failure occurred in 36% of patients, with no difference between BCR and PERS groups. Among those with treatment failure, 64% were [⁶⁸Ga]Ga-PSMA-11 PET/CT positive at recurrence, and 39% received a new PSMA PET/CT-based RT. All patients were alive at the last analysis. CONCLUSION: [⁶⁸Ga]Ga-PSMA-11 PET/CT-guided sRT demonstrates significant long-term efficacy in patients with BCR or PERS after RP, leading to durable PSA response and guiding further treatment decisions. TRIAL REGISTRATION: 244/2016/O/Oss8 November 2016 retrospectively registered.
引用
- Di Giorgio A, Siepe G, Serani F, et al. Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40186765. doi:10.1007/s00259-025-07255-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。